BSE: 531739 | NSE: | Pharmaceuticals & Drugs | Small Cap
Past 10 year’s financial track record analysis by Moneyworks4me indicates that Gennex Laboratories Ltd is a below average quality company.
The key valuation ratios of Gennex Laboratories Ltd's currently when compared to its past seem to suggest it is in the Overvalued zone.
The Price Trend analysis by MoneyWorks4Me indicates it is Weak which suggest that the price of Gennex Laboratories Ltd is likely to Fall in the short term. However, please check the rating on Quality and Valuation before investing.
Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end.
| Mar'15 | Mar'16 | Mar'17 | Mar'18 | Mar'19 | Mar'20 | Mar'21 | Mar'22 | Mar'23 | Mar'24 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROCE % ⓘ | 4.6% | 11.8% | 11.6% | 6.3% | 10.5% | 8.3% | 13.2% | 11.8% | 10.7% | 12.5% | - |
| Value Creation Index ⓘ | -0.7 | -0.2 | -0.2 | -0.6 | -0.3 | -0.4 | -0.1 | -0.2 | -0.2 | -0.1 | - |
Growth Parameters ⓘGrowth Parameters Colour Code Guide ⓘ | |||||||||||
| Sales ⓘ | 31.9 | 38.6 | 41.9 | 43.8 | 55.8 | 55.6 | 59.7 | 61.2 | 65.1 | 66.8 | 84 |
| Sales YoY Gr. | - | 20.9% | 8.7% | 4.5% | 27.5% | -0.3% | 7.3% | 2.6% | 6.4% | 2.6% | - |
| Adj EPS ⓘ | 0.1 | 0.2 | 0.2 | 0.1 | 0.2 | 0.1 | 0.3 | 0.3 | 0.2 | 0.5 | 0.7 |
| YoY Gr. | - | 260% | 16.7% | -71.4% | 183.3% | -29.4% | 158.3% | -9.7% | -14.3% | 112.5% | - |
| BVPS (₹) ⓘ | 1.9 | 2.1 | 2.3 | 2.4 | 2.6 | 2.7 | 3 | 3.3 | 4.5 | 7.3 | 7.6 |
| Adj Net Profit ⓘ | 0.6 | 2.4 | 2.7 | 0.9 | 2.2 | 1.6 | 4.1 | 3.7 | 4.2 | 11.7 | 15 |
| Cash Flow from Ops. ⓘ | 0.2 | 3.4 | -0.1 | 3.2 | 1.9 | -1.7 | -1.4 | 6.6 | -14.5 | -33.4 | - |
| Debt/CF from Ops. ⓘ | 18.6 | 0.7 | -36.2 | 0.8 | 2.4 | -3 | -5.1 | 1.5 | -0.2 | -0.1 | - |
CAGR Colour Code Guide ⓘ
| 9 Years | 5 Years | 3 Years | 1 Years | |||||
|---|---|---|---|---|---|---|---|---|
| Sales ⓘ | 8.6% | 3.7% | 3.9% | 2.6% | ||||
| Adj EPS ⓘ | 29.4% | 24.6% | 18.1% | 112.5% | ||||
| BVPSⓘ | 15.9% | 23.2% | 34.1% | 63.2% | ||||
| Share Price | 18.6% | 47.5% | 29.7% | 5.9% | ||||
Performance Ratio Colour Code Guide ⓘ
| Mar'15 | Mar'16 | Mar'17 | Mar'18 | Mar'19 | Mar'20 | Mar'21 | Mar'22 | Mar'23 | Mar'24 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Return on Equity % ⓘ | 2.5 | 8.7 | 9.2 | 2.7 | 6.7 | 4.7 | 10.7 | 8.7 | 6.9 | 9.4 | 8.7 |
| Op. Profit Mgn % ⓘ | 6.3 | 10.9 | 10.9 | 5.2 | 7.2 | 5.8 | 11 | 8.8 | 7 | 18.6 | 18 |
| Net Profit Mgn % ⓘ | 2 | 6.1 | 6.5 | 2 | 4 | 2.9 | 6.8 | 6 | 6.5 | 17.5 | 17.5 |
| Debt to Equity ⓘ | 0.2 | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | 0.2 | 0.2 | 0 | 0 | 0 |
| Working Cap Days ⓘ | 181 | 160 | 185 | 203 | 161 | 184 | 204 | 213 | 249 | 436 | 361 |
| Cash Conv. Cycle ⓘ | -12 | 6 | 10 | 2 | 15 | 33 | 25 | 43 | 70 | 60 | 297 |
Return on Equity has increased versus last 3 years average to 8.70%
Net Profit is growing at healthy rate in last 3 years 18.05%
Sales growth is good in last 4 quarters at 41.16%
Sales growth has been subdued in last 3 years 3.85%
| Standalone | Consolidated | |
|---|---|---|
| TTM EPS (₹) | 0.7 | 0.7 |
| TTM Sales (₹ Cr.) | 84.4 | 113 |
| BVPS (₹.) ⓘ | 7.6 | 7.7 |
| Reserves (₹ Cr.) ⓘ | 151 | 152 |
| P/BV ⓘ | 2.25 | 2.23 |
| PE ⓘ | 26.20 | 23.29 |
| From the Market | |
|---|---|
| 52 Week Low / High (₹) | 13.25 / 29.00 |
| All Time Low / High (₹) | 0.22 / 29.00 |
| Market Cap (₹ Cr.) | 390 |
| Equity (₹ Cr.) | 22.7 |
| Face Value (₹) | 1 |
| Industry PE ⓘ | 44.3 |
| Pledged * | 8.07 | 8.84 | 3.46 | 3.46 | 34.17 | 34.14 | 0.00 | 0.00 | 0.00 | 0.00 |
| PARTICULARS | Mar'15 | Mar'16 | Mar'17 | Mar'18 | Mar'19 | Mar'20 | Mar'21 | Mar'22 | Mar'23 | Mar'24 |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 32 | 39 | 42 | 44 | 56 | 56 | 60 | 61 | 65 | 67 |
| Operating Expenses ⓘ | 30 | 34 | 37 | 42 | 52 | 52 | 53 | 56 | 61 | 54 |
| Manufacturing Costs | 4 | 5 | 5 | 6 | 8 | 8 | 6 | 6 | 8 | 6 |
| Material Costs | 20 | 23 | 24 | 27 | 33 | 34 | 36 | 38 | 40 | 38 |
| Employee Cost | 3 | 4 | 5 | 6 | 6 | 7 | 7 | 7 | 8 | 6 |
| Other Costs ⓘ | 2 | 3 | 4 | 4 | 5 | 4 | 4 | 4 | 5 | 3 |
| Operating Profit ⓘ | 2 | 4 | 5 | 2 | 4 | 3 | 7 | 5 | 5 | 12 |
| Operating Profit Margin (%) | 6.3% | 10.9% | 10.8% | 5.0% | 7.2% | 5.8% | 11.0% | 8.8% | 7.0% | 18.6% |
| Other Income ⓘ | 0 | 0 | 0 | 1 | 1 | 1 | 1 | 1 | 3 | 4 |
| Interest ⓘ | 0 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| Depreciation ⓘ | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| Exceptional Items ⓘ | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Profit Before Tax ⓘ | 1 | 3 | 3 | 1 | 3 | 3 | 5 | 5 | 6 | 15 |
| Tax ⓘ | 0 | 1 | 0 | 1 | 1 | 1 | 1 | 1 | 1 | 3 |
| Profit After Tax | 1 | 2 | 3 | 1 | 2 | 2 | 4 | 4 | 5 | 12 |
| PAT Margin (%) | 2.1% | 6.1% | 6.5% | 1.9% | 4.0% | 3.3% | 6.8% | 6.4% | 7.0% | 17.7% |
| Adjusted EPS (₹) | 0.1 | 0.2 | 0.2 | 0.1 | 0.2 | 0.1 | 0.3 | 0.3 | 0.3 | 0.5 |
| Dividend Payout Ratio (%) | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
| PARTICULARS | Mar'15 | Mar'16 | Mar'17 | Mar'18 | Mar'19 | Mar'20 | Mar'21 | Mar'22 | Mar'23 | Mar'24 |
|---|---|---|---|---|---|---|---|---|---|---|
Equity and Liabilities | ||||||||||
| Shareholders Fund | 26 | 28 | 31 | 32 | 34 | 36 | 40 | 44 | 79 | 165 |
| Share Capital ⓘ | 13 | 13 | 13 | 13 | 13 | 13 | 13 | 13 | 18 | 23 |
| Reserves ⓘ | 13 | 16 | 18 | 19 | 21 | 23 | 27 | 31 | 61 | 142 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Debt | 4 | 2 | 4 | 3 | 5 | 5 | 7 | 10 | 2 | 3 |
| Long Term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 2 |
| Short Term Debt | 3 | 2 | 4 | 2 | 5 | 5 | 7 | 10 | 1 | 1 |
| Trade Payables | 7 | 7 | 9 | 12 | 8 | 8 | 6 | 8 | 6 | 14 |
| Others Liabilities ⓘ | 3 | 4 | 5 | 4 | 5 | 8 | 6 | 6 | 8 | 23 |
| Total Liabilities ⓘ | 39 | 42 | 49 | 50 | 52 | 57 | 59 | 68 | 96 | 205 |
Fixed Assets | ||||||||||
| Gross Block | 26 | 27 | 28 | 29 | 30 | 30 | 30 | 31 | 33 | 34 |
| Accumulated Depreciation | 12 | 12 | 12 | 13 | 14 | 15 | 16 | 17 | 17 | 18 |
| Net Fixed Assetsⓘ | 15 | 15 | 16 | 16 | 16 | 15 | 14 | 14 | 15 | 16 |
| CWIP ⓘ | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
| Investmentsⓘ | 7 | 7 | 7 | 7 | 7 | 7 | 7 | 7 | 8 | 8 |
| Inventories | 1 | 3 | 3 | 2 | 5 | 7 | 5 | 8 | 15 | 16 |
| Trade Receivables | 6 | 7 | 10 | 10 | 10 | 6 | 8 | 11 | 9 | 14 |
Cash Equivalents  ⓘ
| 1 | 1 | 1 | 1 | 3 | 1 | 1 | 8 | 14 | 61 |
| Others Assetsⓘ | 9 | 8 | 13 | 14 | 10 | 21 | 24 | 20 | 34 | 89 |
| Total Assets ⓘ | 39 | 42 | 49 | 50 | 52 | 57 | 59 | 68 | 96 | 205 |
| PARTICULARS | Mar'15 | Mar'16 | Mar'17 | Mar'18 | Mar'19 | Mar'20 | Mar'21 | Mar'22 | Mar'23 | Mar'24 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash Flow From Operating Activity ⓘ | 0 | 3 | 0 | 3 | 2 | -2 | -1 | 7 | -14 | -33 |
| PBT ⓘ | 1 | 3 | 3 | 1 | 3 | 3 | 5 | 5 | 6 | 15 |
| Adjustment ⓘ | 1 | 1 | 2 | 2 | 2 | 2 | 2 | 3 | -1 | -2 |
| Changes in Working Capital ⓘ | -2 | -1 | -4 | 1 | -3 | -6 | -7 | -0 | -20 | -45 |
| Tax Paid ⓘ | 0 | 0 | -1 | -1 | 0 | 0 | -2 | -1 | 0 | -1 |
| Cash Flow From Investing Activity ⓘ | 0 | -1 | -1 | -1 | -1 | 0 | 0 | -1 | -1 | 1 |
| Capex | 0 | -1 | -1 | -1 | -1 | 0 | 0 | 0 | -2 | -3 |
| Net Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -1 | 0 |
| Others ⓘ | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -1 | 3 | 4 |
| Cash Flow From Financing Activityⓘ | 0 | -2 | 1 | -2 | 1 | 0 | 2 | 2 | 21 | 79 |
| Net Proceeds from Shares ⓘ | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 30 | 80 |
| Net Proceeds from Borrowing ⓘ | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 |
| Interest Paid ⓘ | 0 | -1 | -1 | -1 | -1 | -1 | -1 | -1 | -1 | -1 |
| Dividend Paid ⓘ | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Others ⓘ | 1 | -1 | 2 | -2 | 2 | 0 | 2 | 3 | -9 | 0 |
| Net Cash Flow ⓘ | 0 | 0 | 0 | 0 | 2 | -2 | 0 | 7 | 6 | 47 |
| PARTICULARS | Mar'15 | Mar'16 | Mar'17 | Mar'18 | Mar'19 | Mar'20 | Mar'21 | Mar'22 | Mar'23 | Mar'24 |
|---|---|---|---|---|---|---|---|---|---|---|
| Ratios | ||||||||||
| ROE (%) | 2.57 | 8.69 | 9.14 | 2.67 | 6.75 | 5.32 | 10.66 | 9.35 | 7.43 | 9.68 |
| ROCE (%) | 4.57 | 11.78 | 11.61 | 6.31 | 10.49 | 8.32 | 13.18 | 11.78 | 10.7 | 12.5 |
| Asset Turnover Ratio | 0.85 | 1 | 0.96 | 0.95 | 1.17 | 1.1 | 1.1 | 1.03 | 0.87 | 0.49 |
| PAT to CFO Conversion(x) | 0 | 1.5 | 0 | 3 | 1 | -1 | -0.25 | 1.75 | -2.8 | -2.75 | Working Capital Days |
| Receivable Days | 60 | 60 | 72 | 80 | 63 | 51 | 40 | 53 | 52 | 55 |
| Inventory Days | 17 | 19 | 24 | 20 | 23 | 39 | 36 | 36 | 58 | 77 |
| Payable Days | 129 | 111 | 126 | 148 | 113 | 88 | 72 | 66 | 65 | 99 |
Gennex Laboratories (formerly Prudential Pharmaceuticals) is a public limited company established in the year 1995 and has been engaged in the manufacturing of bulk drugs and intermediates. The company started as one of the leading manufacturer and exporter of bulk drugs and intermediates. Quality is the strength of the company and major part of its finished products are exported to various countries viz. Germany, United Kingdom, Spain, Singapore, Canada, Switzerland, Iran, Bangladesh, Pakistan and other major countries. Gennex Laboratories has diversified its activities to biotech products in order to have better prospects and opportunities for the company for expanding its bussiness activities and to meet the marketing requirements.
The company had commenced its commercial operations of Guaifenesin in November, 1995 and in a span of about one and half years, it was able to capture about 70% of the domestic market mainly due to the impeccable quality, aggressive marketing strategies, cost effective manufacturing and efficient distribution cum market penetration. It has also established itself fairly well in the export market and recognized well by many end-users and trading giants of international market.
The company has catered to countries like USA, Mexico, Spain and Germany and the quality has been accepted and appreciated extremely well with all the customers. Several customers have evinced interest on long-term tie-ups. Slowly but surely, the company is constantly expanding its reach to USA and European markets and it has been receiving very encouraging enquiries from prospective customers based on quality recommendations by existing customers. The company’s headquarters is situated in the heart of the city and the factory is situated at Survey No 133, IDA Bollaram, Jinnaram Mandal, Medak District-502 325, Andhra Pradesh, India. The factory occupies a total land area of 8,000 square meters. The total building floor space is1,945 square meters. The storage space is 500 square meters. The central lab has a floor space of 225 square meters.
Products of the company:
Certification:
MoneyWorks4Me rating and ranking of funds for SIP is available to subscribers only. Moneyworks4Me is not a rating and ranking agency, however it is required that users have a way of selecting funds and building a Portfolio. The method used by it are described below to enable users to understand the logic behind the rating and ranking Subscriber will find more details on this in the various content made available from time to time. In case you need more please write to besafe@moneyworks4Me.com
MoneyWorks4Me rates and ranks mutual funds based on the following data-driven system:
Funds ranking in screeners: Performance Consistency and Quality are two parameters used for ranking funds for SIP. The ranking as follows GG, GO, GR, OG, OO, OR, RG, RO and RR.
With the same color-coded funds, the one with the higher Average 3-year rolling returns (over 5 to 10 years), the number that appears in the Performance tag, ranks higher.
Here is the summary:
The third tag Upside Potential is not relevant for SIP. It is relevant for lumpsum investments in Mutual Funds.
Make an informed decision for Stocks
Invest using an intelligent system with powerful data-driven tools that help you identify opportunities and make informed buy-hold-sell decisions
Buy quality Stocks when they are available at reasonable prices and supported by an upward price trend and Sell when they are Overvalued using the Decizen Rating System. Covers 3500+ stocks
Limited to the first 10 users today!
Practical Stock Investing Hand Book
By - Raymond Moses
Founder of MoneyWorks4Me | Consultant | Trainer | Author | TEDx Speaker
Register & Get Instant Access!Don't miss out! First 10 users today get it FREE
With this 4 hrs Masterclass, you’ll be able to:
Download APP
